 SEATTLE, Feb. 23, 2021 GLOBE NEWSWIRE -- Adaptive Biotechnologies Corporation Nasdaq: ADPT, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an expansion of its collaboration with Labcorp NYSE:LH, a leading global life sciences company, to enable broader access to Adaptives growing portfolio of immune-driven clinical diagnostic and research products. The expanded collaboration includes a commercial agreement for Adaptives clonoSEQ and immunoSEQ assays and a lab services agreement for Adaptives recently launched T-Detect COVIDTM test, the first clinical T-cell based test for patients to confirm recent or prior COVID-19 infection. 